Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review

Seeking AlphaJan 12 07:44 ET

XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC

RTTNewsJan 11 21:02 ET

LadRx Issues 2024 Update to Shareholders

FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer

BusinesswireJan 9 08:00 ET

XOMA Acquires Drug Rights From LadRx for $5M

Seeking AlphaJun 22, 2023 12:23 ET

XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx

XOMA (XOMA) said Thursday it has acquired the royalty and milestone rights for two assets from LadRx for $5 million. The assets are arimoclomol, an investigational treatment for neurogenerative disord

MT NewswiresJun 22, 2023 10:03 ET

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 O

BenzingaJun 22, 2023 07:39 ET